Abstract accepted at the American Society of Clinical Oncology (ASCO) Annual Meeting - the world’s largest and most ...

ACAPELLA is the European multicenter clinical trial evaluating Alpha DaRT alpha-emitter radiotherapeutics combined with capecitabine for ...

IDE supplement expands trial to the other primary standard-of-care chemotherapy for pancreatic cancer patients, alongside mFOLFIRINOX -- IDE ...

Alpha Tau Medical Ltd ( (DRTS)) has issued an announcement. On April 23, 2026, Alpha Tau Medical announced that it has successfully treated the first European pancreatic cancer patient with its Alpha ...

Greetings, and welcome to the Mirion Technologies' First Quarter 2026 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to ...

NAGASAKI -- A team of researchers at Nagasaki University's graduate school has announced that radiation from uranium ...

Targeted Alpha Therapies present growth opportunities by targeting cancer with specificity and efficacy. Key prospects include advancements in clinical trials, exploring combination therapies, ...

Breakthroughs in identifying tumor biomarkers in liver, gastric, prostate, lung and other cancers and are accelerating ...

The rise of a new generation of radiotherapies means we will soon need much greater quantities of radioactive atoms. That's ...

Rocket Lab offers a compelling growth narrative, contingent on sustained 40–50%+ revenue growth. Read more on the buy thesis ...

Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation alpha-emitting radioantibodies for the treatment of advanced prostate cancer, today announced that ...

If an alien in the Alpha Centauri star system were craving pizza, it would take tens of thousands of years to deliver it ...